Suyash Prasad, CMO and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 157,200 shares at $23.74 ($3.6M) on 2021-06-29, disclosed to the SEC on 2021-07-01.
Open-market sale of $3.6M TSHA by CMO and Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.74 | 35,056 | $832K | 23.4% |
| 2 | $23.74 | 35,056 | $832K | 23.4% |
| 3 | $24.46 | 3,862 | $94K | 2.7% |
| 4 | $24.46 | 3,862 | $94K | 2.7% |
| 5 | $25.19 | 300 | $8K | 0.2% |
| 6 | $21.42 | 13,374 |
| $286K |
| 8.1% |
| 7 | $21.42 | 13,374 | $286K | 8.1% |
| 8 | $22.44 | 6,202 | $139K | 3.9% |
| 9 | $22.44 | 6,202 | $139K | 3.9% |
| 10 | $23.70 | 500 | $12K | 0.3% |
| 11 | $21.12 | 19,706 | $416K | 11.7% |
| 12 | $21.12 | 19,706 | $416K | 11.7% |
| Total | $22.62 avg | 157,200 | $3.6M | 100% |
| Filing → |
| BOLD | SELL | 2019-05-15 | $738K | — | Filing → |
| BOLD | SELL | 2019-02-27 | $301K | — | Filing → |
| BOLD | SELL | 2018-10-02 | $536K | — | Filing → |